View Older Stories View More Recent Stories

Feb 1, 2018 04:04PM Alnylam Pharma (ALNY) Announces FDA Acceptance NDA and Priority Review Status for Patisiran
Feb 1, 2018 04:00PM Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Feb 1, 2018 07:00AM Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results
Jan 25, 2018 04:01PM Alnylam Pharma (ALNY) Announces EMA Acceptance of MAA for Patisiran for hATTR Amyloidosis
Jan 25, 2018 04:00PM Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Jan 8, 2018 05:55AM Alnylam Pharma (ALNY) Releases Corporate Goals for 2018
Jan 8, 2018 05:53AM Alnylam Pharma (ALNY) and Sanofi (SNY) Report Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Jan 7, 2018 03:30PM Alnylam Announces 2018 Corporate Goals
Jan 7, 2018 03:01PM Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
Jan 7, 2018 03:00PM Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
Jan 7, 2018 03:00PM Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Jan 4, 2018 04:00PM Alnylam Expands Alnylam Act™ Program to Include No-Charge Third-Party Genetic Testing and Counseling for People at Risk for Acute Hepatic Porphyrias
Jan 2, 2018 04:00PM Alnylam to Webcast Presentation at 36th Annual J.P. Morgan Healthcare Conference
Dec 28, 2017 04:00PM Alnylam to Webcast Presentation at Goldman Sachs Healthcare CEOs Unscripted Conference
Dec 18, 2017 07:04AM Sanofi (SNY) and Alnylam (ALNY) Submit EU Marketing Authorization Application for Patisiran to Treat hATTR amyloidosis
Dec 18, 2017 07:04AM Alnylam Pharma (ALNY) & Sanofi (SNY) Announce Marketing Authorisation Application to EMA for Patisiran for Treatment of Hereditary ATTR Amyloidosis
Dec 18, 2017 07:01AM Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
Dec 18, 2017 07:00AM Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
Dec 18, 2017 07:00AM Alnylam and Sanofi Submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Dec 15, 2017 07:03AM Alnylam Pharma (ALNY) and Sanofi Genzyme (SNY) Reports Lift of FDA Hold on Fitusiran
Dec 15, 2017 07:03AM Sanofi (SNY) and Alnylam (ALNY) Announce FDA Lifted Clinical hold on Fitusiran
Dec 15, 2017 07:01AM Sanofi: FDA lifts clinical hold on fitusiran
Dec 15, 2017 07:00AM Sanofi: FDA lifts clinical hold on fitusiran
Dec 15, 2017 07:00AM FDA Lifts Clinical Hold on Fitusiran
Dec 12, 2017 07:10AM Alnylam Pharma (ALNY) Completes Submission of NDA to FDA for Patisiran for Treatment of Hereditary ATTR (hATTR) Amyloidosis
Dec 12, 2017 07:00AM Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Dec 11, 2017 07:05AM Alnylam Pharma (ALNY) Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of ATTR Amyloidosis
Dec 11, 2017 07:00AM Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis
Dec 7, 2017 04:00PM Alnylam to Webcast Presentation at BMO Capital Markets Prescriptions for Success Healthcare Conference
Nov 20, 2017 07:01AM Alnylam Pharma (ALNY) Granted FDA Breakthrough Therapy Designation for Patisiran
Nov 20, 2017 07:00AM U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
Nov 16, 2017 07:08AM Alnylam Pharma (ALNY) Commences Rolling Submission of New Drug Application FDA for Patisiran
Nov 16, 2017 07:00AM Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Nov 13, 2017 07:33AM Alnylam Pharma (ALNY) Granted Accelerated Assessment of Patisiran by EMA
Nov 13, 2017 07:30AM European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis
Nov 9, 2017 04:00PM Alnylam Pharma (ALNY) Announces Successful Outcome Following FDA Type A Meeting on Fitusiran Program
Nov 9, 2017 04:00PM Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia
Nov 7, 2017 04:00PM Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity
Nov 7, 2017 07:09AM Alnylam Pharma (ALNY) Initiates ENVISION Phase 3 Clinical Study with Givosiran to Treat AHPs
Nov 7, 2017 07:00AM Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
Nov 6, 2017 07:16AM Medicines Co. (MDCO), Alnylam Pharmaceuticals (ALNY) Announce Initiation of Phase III Clinical Trials of Inclisiran
Nov 6, 2017 07:00AM The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
Nov 3, 2017 11:00AM Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 (PH1)
Nov 2, 2017 10:46AM Alnylam Pharma (ALNY), Sanofi (SNY) Present Positive Complete Results from APOLLO Phase 3 Study of Investigational Patisiran in hATTR Amyloidosis Patients with Polyneuropathy
Nov 2, 2017 10:46AM Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
Nov 2, 2017 10:45AM Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
Nov 2, 2017 10:45AM Alnylam and Sanofi Present Positive Complete Results from APOLLO Phase 3 Study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Oct 31, 2017 04:00PM Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Oct 30, 2017 04:00PM Alnylam to Webcast Conference Call Discussing Third Quarter 2017 Financial Results
Oct 20, 2017 07:00AM Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors
View More Recent Stories View Older Stories